Foundayo: A New Oral GLP-1 Option for Obesity

Foundayo (orforglipron), from Eli Lilly, is the first FDA-approved daily oral GLP-1 receptor agonist pill for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions like hypertension or type 2 diabetes. 

Unlike injections or food-restricted orals, it offers flexible dosing anytime, boosting potential adherence in long-term weight management.

FDA Approval Highlights

Approved on April 1, 2026, Foundayo earned the fastest new molecular entity nod under the National Priority Voucher program—see FDA announcement and Eli Lilly press release. It's indicated with diet/exercise; shipping starts April 6 via LillyDirect.

Dosing and Titration Schedule

Foundayo starts low to minimize gastrointestinal side effects, titrating over weeks based on tolerance and response (max 17.2 mg daily).

Week	Dose (mg)	Notes
1-2	0.8	Starting dose; take once daily
3-4	2.2	Increase if tolerated
5-6	4.9	Monitor for nausea
7-8	8.1	Flexible timing
9+	10.6-17.2	Target/maintenance; adjust per response

Clinical Efficacy

Phase 3 ATTAIN-1 trial (n>4,500) showed 12.4% body weight loss (27 lbs average) on highest dose vs. 2% placebo at 72 weeks—detailed in NEJM publication. 

Improvements persisted; 65% achieved ≥10% loss.

Cardiometabolic Benefits

Foundayo reduced waist circumference, triglycerides, non-HDL cholesterol, systolic blood pressure, and hsCRP. TRIUMPH outcomes trial assesses MACE in ASCVD patients, aligning with GLP-1 class CV protection.

Safety Profile

GI effects (nausea 20-30%, diarrhea, vomiting) peak early and wane; similar to injectables. Warnings: thyroid C-cell tumors, pancreatitis, gallbladder issues. Avoid with other GLP-1s; monitor hypoglycemia with insulin.

Pricing and Access

Option	Monthly Cost	Details
Commercial Insurance + Savings Card	$25	Most pay this via Lilly
Self-Pay (LillyDirect)	$149 (0.8 mg) to $349 (17.2 mg)	Tiered by dose
Medicare Part D	~$50 by July 2026	Expected post-negotiation

Clinical Implications

For cardiologists, Foundayo offers a patient-friendly GLP-1 to tackle obesity-driven CV risk. Its pill form may widen access beyond Zepbound users, with scalable manufacturing aiding global reach. Monitor adherence and titrate carefully.